Menu

Theranos Goes Under

The discredited blood-testing company announced its decision to close in a company-wide email.

Sep 5, 2018
Sukanya Charuchandra
Elizabeth Holmes

The blood-testing company Theranos will be dissolving and returning its remaining cash (approximately $5 million) to its creditors, reports The Wall Street Journal

The troubled company’s CEO and general counsel, David Taylor, made the declaration in an email to shareholders and said, “I write with difficult news about the future of the Company.” The firm’s remaining employees worked their last day on August 31. 

The move comes after Theranos failed to secure a buyer or further investments and ended up breaking the terms of its $65 million loan from Fortress Investment Group. By brokering of a deal with the investment firm, Theranos gets to consolidate its leftover money in a trust for creditors that might take between six to 12 months to process. The email states, “Because the Company’s cash is not nearly sufficient to pay all of its creditors in full, there will be no distributions to shareholders.” 

Three months ago, Theranos’s founder Elizabeth Holmes and former CEO Ramesh Balwani faced criminal charges for committing a multimillion-dollar fraud against investors, doctors, and patients. According to Financial Times, Holmes resigned immediately following the indictment. Among the company’s most well-known investors were Rupert Murdoch, Walmart’s Walton family, and the family of Betsy DeVos.

The criminal charges are in addition to the Securities and Exchange Commission’s civil charges against Theranos, Holmes, and Balwani for defrauding investors of $700 million, a case that Balwani is still fighting. 

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.